NRx Pharmaceuticals Highlights Real-World Ketamine Depression Data
MIAMI, June 5, 2026 NRx Pharmaceuticals, Inc. announced that new real-world evidence presented at the 2026 American Society of...
Psychiatry
Advertisement
Definium Therapeutics Begins Phase 3 DT120-ODT Study
WALTHAM, Mass., May 12, 2026 Definium Therapeutics announced that the first patient has been dosed in the pivotal ASCEND...
Johnson & Johnson Highlights CAPLYTA Superiority in MDD Study
TITUSVILLE, NEW JERSEY, May 04, 2026 Johnson & Johnson has announced new findings demonstrating that CAPLYTA® (lumateperone) achieved the...
FDA Clears CAPLYTA® as New Adjunctive Therapy for Depression
Titusville, New Jersey – November 6, 2025 – Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and...
Advertisement
